Millions of prescription eye drops recalled nationwide over contamination concerns

Lupin Pharmaceuticals Inc. has initiated a nationwide recall of more than 2.5 million bottles of prednisolone acetate ophthalmic suspension due to the discovery of foreign material in certain lots. The U.S. Food and Drug Administration (FDA) has classified the action as a Class II recall, indicating that the product may cause temporary or medically reversible adverse health consequences. This significant recall highlights ongoing quality control challenges within the pharmaceutical supply chain, particularly for sterile ophthalmic products manufactured at international facilities.

Lupin Pharmaceuticals Inc. is voluntarily recalling 2,530,182 bottles of its prednisolone acetate ophthalmic suspension USP, 1%, a prescription corticosteroid used to treat eye inflammation resulting from surgery, injury, or specific medical conditions. The recall affects 5 mL, 10 mL, and 15 mL bottles distributed across the United States under National Drug Codes 70748-332-02, 70748-332-03, and 70748-332-04. The FDA designated this as a Class II recall on June 30, 2026, a category used when a product's use could lead to temporary health issues or where the risk of serious harm is considered remote.

The contamination issue was traced back to products manufactured by Lupin Limited at its facility in Pithampur, India. The recall encompasses dozens of lot numbers with expiration dates ranging from July 2026 through October 2026 and beyond. While Lupin initiated the recall process on June 4 by notifying customers via letter, the company has not yet issued a formal press release regarding the incident. The FDA’s enforcement report confirms that the recall remains ongoing as the agency and the manufacturer work to remove the potentially contaminated units from the market.

For the pharmaceutical sector, this massive recall underscores the critical importance of sterile manufacturing processes and the regulatory scrutiny facing international production sites. Patients are being advised not to discontinue their medication without consulting a healthcare professional, as prednisolone acetate is a vital steroid for managing post-surgical recovery and inflammatory eye diseases. Healthcare providers and pharmacists are currently tasked with cross-referencing lot numbers against the FDA’s enforcement report to identify affected stock and facilitate replacements for concerned patients.